AllSquare Wealth Management’s Thermo Fisher Scientific TMO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | $47K | Hold |
97
| – | – | 0.02% | 239 |
|
|
2025
Q2 | $39.3K | Hold |
97
| – | – | 0.02% | 249 |
|
|
2025
Q1 | $48.3K | Hold |
97
| – | – | 0.03% | 213 |
|
|
2024
Q4 | $50.5K | Hold |
97
| – | – | 0.03% | 210 |
|
|
2024
Q3 | $60K | Hold |
97
| – | – | 0.03% | 195 |
|
|
2024
Q2 | $53.6K | Hold |
97
| – | – | 0.03% | 198 |
|
|
2024
Q1 | $56.4K | Hold |
97
| – | – | 0.03% | 202 |
|
|
2023
Q4 | $51.5K | Hold |
97
| – | – | 0.03% | 209 |
|
|
2023
Q3 | $49.1K | Hold |
97
| – | – | 0.03% | 194 |
|
|
2023
Q2 | $49.9K | Hold |
97
| – | – | 0.03% | 205 |
|
|
2023
Q1 | $55.9K | Sell |
97
-105
| -52% | -$59.2K | 0.04% | 192 |
|
|
2022
Q4 | $111K | Buy |
202
+23
| +13% | +$12.2K | 0.08% | 126 |
|
|
2022
Q3 | $91K | Buy |
179
+35
| +24% | +$19.6K | 0.07% | 131 |
|
|
2022
Q2 | $78K | Hold |
144
| – | – | 0.05% | 157 |
|
|
2022
Q1 | $85K | Buy |
144
+2
| +1% | +$1.15K | 0.05% | 165 |
|
|
2021
Q4 | $95K | Sell |
142
-9
| -6% | -$5.62K | 0.06% | 159 |
|
|
2021
Q3 | $86K | Sell |
151
-47
| -24% | -$25.8K | 0.05% | 168 |
|
|
2021
Q2 | $100K | Hold |
198
| – | – | 0.06% | 158 |
|
|
2021
Q1 | $90K | Buy |
198
+4
| +2% | +$1.91K | 0.06% | 161 |
|
|
2020
Q4 | $90K | Hold |
194
| – | – | 0.06% | 147 |
|
|
2020
Q3 | $86K | Hold |
194
| – | – | 0.06% | 140 |
|
|
2020
Q2 | $70K | Sell |
194
-26
| -12% | -$8.71K | 0.05% | 149 |
|
|
2020
Q1 | $62K | Hold |
220
| – | – | 0.05% | 146 |
|
|
2019
Q4 | $71K | Sell |
220
-34
| -13% | -$10.3K | 0.05% | 151 |
|
|
2019
Q3 | $74K | Hold |
254
| – | – | 0.05% | 152 |
|
|
2019
Q2 | $75K | Buy |
254
+159
| +167% | +$43.8K | 0.06% | 149 |
|
|
2019
Q1 | $26K | Hold |
95
| – | – | 0.02% | 245 |
|
|
2018
Q4 | $21K | Hold |
95
| – | – | 0.02% | 246 |
|
|
2018
Q3 | $23K | Hold |
95
| – | – | 0.02% | 254 |
|
|
2018
Q2 | $20K | Buy |
95
+65
| +217% | +$13.8K | 0.02% | 274 |
|
|
2018
Q1 | $6K | Hold |
30
| – | – | ﹤0.01% | 320 |
|
|
2017
Q4 | $6K | Hold |
30
| – | – | ﹤0.01% | 319 |
|
|
2017
Q3 | $6K | Buy |
+30
| New | +$5.43K | ﹤0.01% | 302 |
|
|
2017
Q2 | – | Sell |
-30
| Closed | -$5K | – | 346 |
|
|
2017
Q1 | $5K | Sell |
30
-346
| -92% | -$52.9K | ﹤0.01% | 305 |
|
|
2016
Q4 | $53K | Buy |
376
+55
| +17% | +$8.11K | 0.05% | 130 |
|
|
2016
Q3 | $51K | Buy |
321
+54
| +20% | +$8.32K | 0.05% | 118 |
|
|
2016
Q2 | $39K | Hold |
267
| – | – | 0.04% | 130 |
|
|
2016
Q1 | $38K | Hold |
267
| – | – | 0.04% | 130 |
|
|
2015
Q4 | $38K | Buy |
267
+133
| +99% | +$17.7K | 0.04% | 129 |
|
|
2015
Q3 | $16K | Buy |
134
+104
| +347% | +$13.5K | 0.02% | 189 |
|
|
2015
Q2 | $4K | Hold |
30
| – | – | ﹤0.01% | 286 |
|
|
2015
Q1 | $4K | Hold |
30
| – | – | ﹤0.01% | 288 |
|
|
2014
Q4 | $4K | Buy |
+30
| New | +$3.65K | ﹤0.01% | 282 |
|
Other funds holding TMO
AllSquare Wealth Management's TMO Position: Q3 2025 in Review
AllSquare Wealth Management held its Thermo Fisher Scientific (TMO) position steady in Q3 2025 at 97 shares worth $47K. The position accounts for 0.02% of the portfolio, ranked #239.
AllSquare Wealth Management first reported a position in TMO in Q4 2014 and has held it in 43 quarters since. The position peaked at $111K in Q4 2022. 2,508 funds tracked by Wall St. Rank hold TMO as of Q3 2025.
- AllSquare Wealth Management held 97 shares of Thermo Fisher Scientific worth $47K as of Q3 2025.
- AllSquare Wealth Management left its Thermo Fisher Scientific share count unchanged in Q3 2025.
- Thermo Fisher Scientific made up 0.02% of AllSquare Wealth Management's portfolio in Q3 2025, its #239 holding.
- AllSquare Wealth Management first reported a position in Thermo Fisher Scientific in Q4 2014 and has held it in 43 quarters since.
- AllSquare Wealth Management's Thermo Fisher Scientific position peaked at $111K in Q4 2022.
- 2,508 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q3 2025.
Based on AllSquare Wealth Management's 13F filing for Q3 2025, filed 12 Jan 2026.